Head to Head Comparison: Agilent Technologies (NYSE:A) vs. biote (NASDAQ:BTMD)

biote (NASDAQ:BTMD) and Agilent Technologies (NYSE:A) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, earnings, risk and analyst recommendations.

Profitability

This table compares biote and Agilent Technologies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
biote	14.72%	-21.86%	15.68%
Agilent Technologies	18.75%	25.20%	12.99%

Risk and Volatility

biote has a beta of 1.15, meaning that its share price is 15% more volatile than the S&P 500. Comparatively, Agilent Technologies has a beta of 1.27, meaning that its share price is 27% more volatile than the S&P 500.

Institutional & Insider Ownership

21.7% of biote shares are owned by institutional investors. Comparatively, 87.4% of Agilent Technologies shares are owned by institutional investors. 24.0% of biote shares are owned by insiders. Comparatively, 0.3% of Agilent Technologies shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of recent recommendations and price targets for biote and Agilent Technologies, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
biote	1	1	1	0	2.00
Agilent Technologies	0	5	9	1	2.73

biote currently has a consensus target price of $6.00, suggesting a potential upside of 135.29%. Agilent Technologies has a consensus target price of $161.08, suggesting a potential upside of 10.75%. Given biote’s higher possible upside, equities research analysts clearly believe biote is more favorable than Agilent Technologies.

Valuation & Earnings

This table compares biote and Agilent Technologies”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
biote	$197.19 million	0.59	$3.16 million	$0.79	3.23
Agilent Technologies	$6.95 billion	5.93	$1.30 billion	$4.57	31.83

Agilent Technologies has higher revenue and earnings than biote. biote is trading at a lower price-to-earnings ratio than Agilent Technologies, indicating that it is currently the more affordable of the two stocks.

Summary

Agilent Technologies beats biote on 12 of the 15 factors compared between the two stocks.

About biote

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support. It also sells dietary supplements under the Biote brand; and sterile pellet insertion kits that is used with hormone optimization therapies for male and female. The company was founded in 2012 and is headquartered in Irving, Texas.

About Agilent Technologies

Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies. The Diagnostics and Genomics segment focuses on genomics, nucleic acid contract manufacturing and research and development, pathology, companion diagnostics, reagent partnership, and biomolecular analysis businesses. The Agilent CrossLab segment provides GC and LC columns, sample preparation products, custom chemistries, and laboratory instrument supplies; and offers services portfolio, including repairs, parts, maintenance, installations, training, compliance support, software as a service, asset management, and consulting services. The company markets its products through direct sales, distributors, resellers, manufacturer’s representatives, and electronic commerce. Agilent Technologies, Inc. was incorporated in 1999 and is headquartered in Santa Clara, California.